HARBIN FUERJIA TECHNOLOGY

Harbin Fuerjia Q3 2026 earnings reveal strong revenue growth but tightening profit margins, spotlighting cost control, inventory buildup, and a new Class‑III medical device roadmap.

Harbin Fuerjia’s stock trades flat at CNY 20.21, hovering above its 200‑day SMA yet below its 52‑week high—signalling short‑term consolidation in China’s tech market.